The one-year results reinforce the interim findings: the mymobility remote care management platform on Apple Watch and iPhone produced similar results to traditional care and led to a reduction in outpatient physiotherapy visits and clinic visits. surgery-related emergencies after knee replacement surgery
WARSAW, Ind., November 5, 2022 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced one-year data from a multicenter, prospective, randomized controlled trial to evaluate the impact of mymobility® with Apple Watch, a unique remote care management platform. Data shows that using mymobility with Apple Watch after primary knee replacement surgery, commonly referred to as knee replacement, can effectively guide rehabilitation, demonstrate similar outcomes to traditional models of care, and significantly reduce physical therapy visits ( PT) outpatients. Additionally, the use of mymobility with Apple Watch was associated with a significant decrease in emergency room visits related to surgery, which may translate into reduced healthcare costs*. The data will be presented during a podium session at the 2022 Annual Meeting of the American Association of Hip and Knee Surgeons (AAHKS).
“We are encouraged to see that the initial positive results from our 90-day analysis were maintained at the one-year follow-up and to continue to reinforce that a remote, mymobility-based care regimen could yield results. comparable for patients and potentially requiring fewer healthcare resources than a traditional model of care,” said David A. CrawfordMD, one of the study’s principal investigators and a joint replacement specialist at JIS Orthopedics in New Albany, Ohio. “With remote smartphone care, patients tend to be more actively engaged in their recovery with access to real-time data to track their progress, and with the ability to communicate more easily with their care teams. through messaging and virtual visits.In the study, these benefits may have contributed to lower utilization of healthcare resources, which may result in cost savings per episode of care.
Data presented at the 2022 AAHKS Annual Meeting evaluated 401 patients who underwent total or partial knee replacement surgery. Patients were randomized into a mymobility group with Apple Watch exercise and education platform, or a control group receiving traditional care. Among the outcomes assessed at the one-year follow-up were knee injury and osteoarthritis outcome score, joint replacement (KOOS, JR), physical therapist visits, readmissions, and primary care visits. emergency/emergency (UC).
Key data findings include:
Patients in the mymobility with Apple Watch group who did not require adjunctive PT had significantly higher KOOS, JR scores compared to controls one year postoperatively (89.3 ± 11.3 vs 83, 8 ± 14.6, p = 0.02).
Significantly fewer patients in the mymobility group with Apple Watch required postoperative physiotherapy (60.6% versus 94.6%, p < 0.001).
Global KOOS, JR scores were similar between the control group and the mymobility with Apple Watch group at one year (83.8 ± 14.6 vs 84.1 ± 14.0, p = 0.88).
The evolution of KOOS, JR scores compared to preoperative levels was similar at one year for the control group and the mymobility group with Apple Watch (32.1±17.4 vs 31.5±17.1 points, p=0 ,51).
Significantly fewer patients in the mymobility with Apple Watch group used surgery-related ED/UC care compared to the control group (1.3% vs. 5.4%, p=0.03).
Similar readmission rates were observed between the mymobility with Apple Watch group and the control group (3.8% vs 2.1%, p=0.36).
“The past two years have brought more focus to the benefits and conveniences of remote care, which is quickly becoming the new normal for many people around the world,” said Nitin Goyal, MD, Director of Science, Technology and Innovation at Zimmer Biomet. “By undertaking a large randomized controlled trial comparing the outcomes associated with a smartphone-based remote model of care versus a traditional model of care, Zimmer Biomet is proud to be at the forefront of efforts to validate platforms, like mymobility with Apple Watch, as a viable alternative. to the standard of care.”
About my mobility® with Apple Watch
mymobility with Apple Watch and iPhone acts as a member of the virtual care team providing patients with support and guidance under the direction of their healthcare professional as they prepare for and recover from orthopedic procedures in comfort of their house. For patients who have a compatible smartphone and are clinically suitable for remote care, mymobility leverages powerful Apple Watch and iPhone sensors to measure a patient’s activity (e.g., step count , gait asymmetry, gait speed, stairs) and postoperative progression. mymobility with Apple Watch also enables virtual connections between patients and healthcare professionals throughout the surgical care episode, with the aim of reducing the overall cost of care. Pre- and post-operative data collected by mymobility with Apple Watch can also be combined with intra-operative data from patients undergoing arthroplasty with ROSA® The robotics are then seamlessly consolidated and analyzed to uncover new clinical insights throughout the care episode and to help surgeons and care teams make informed patient care decisions. Visit zimmerbiomet.com/mymobility to learn more about mymobility with Apple Watch.
About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and our suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
With more than 90 years of trusted leadership and proven expertise, Zimmer Biomet is positioned to provide the highest quality solutions to patients and providers. Our legacy continues to come alive today through our progressive culture of evolution and innovation.
For more information about our product portfolio, operations in over 25 countries, and sales in over 100 countries or to join our team, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, plans, prospects and Zimmer Biomet products. and service offerings, including new product launches and potential clinical successes. These statements are based on management’s current beliefs and expectations and are subject to significant risks, uncertainties and changes in circumstances that could cause actual results to differ materially. For a list and description of some of these risks and uncertainties, see Zimmer Biomet’s periodic reports filed with the United States Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with other cautionary statements included in Zimmer Biomet’s filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this press release are cautioned not to rely on any such forward-looking statements, as there can be no assurance that such forward-looking statements will prove to be accurate. This cautionary statement applies to all forward-looking statements contained in this press release.
*A comparative cost analysis was not part of this study.
Apple Watch and iPhone are registered trademarks of Apple, Inc.
View original content to download multimedia: https://www.prnewswire.com/news-releases/zimmer-biomet-announces-one-year-data-from-mymobility-clinical-study-at-2022-aahks-annual -meeting-301669492.html
SOURCEZimmer Biomet Holdings, Inc.